Follow us...

 

Search News Archives

Monthly Newsletter

 

Lab Bulletin August Newsletter

view the latest issue

Subscribe

News Channels

 

New Laboratory Products

 

Lab News

 

Microscopy & Image Analysis

 

Separation Science

 

Research & Case Studies

 

Literature

 

Videos

 

Events | Webinars

 

 

 

Conferences | Events

Global Human Albumin Market: Extra Revenues to Come through Non-Therapeutic Applications

publication date: Oct 26, 2015
 | 
author/source: Frost & Sullivan

Manufacturers plan to implement premium pricing strategies for commercial use of albumin as an excipient, finds Frost & Sullivan 

Frost and SullivanHuman albumin is widely considered as a plasma replacement or expander for therapeutic purposes. However, for over a decade, the healthcare industry has been exploring the use of human albumin as a non-therapeutic substance/excipient for commercial settings. Across these application areas, emerging opportunities for human albumin as a drug formulation agent, vaccine ingredient, sealant in surgeries, and coating for medical devices and equipment are expected to drive production. 

New analysis from Frost & Sullivan, Analysis of the Global Human Albumin Market and Product Pipeline , finds that the non-therapeutic use of human albumin as an excipient has generated plenty of interest from the industry and will create a potential customer base comprising academics, research institutes, and pharmaceutical and biopharmaceutical companies. Despite this, very few manufacturers, which include large, medium and small enterprises, currently supply human albumin for non-therapeutic applications as an excipient. 

Highly consolidated, the market is dominated by a few top participants. There are about 10 key human albumin products from blood plasma manufacturers that meet the therapeutic use of human albumin in fluid replacement therapy. However, the share of albumin in the blood plasma market has decreased from almost 40 percent in the 1980s to 10 percent in 2015. As human albumin volume growth is expected to slow down during the forecast period, manufacturers will adopt premium pricing in the non-therapeutic application segment to meet their profit margins. 

“When it comes to albumin for replacement therapy, a premium pricing strategy could go in vain,” saidFrost & Sullivan Healthcare Senior Research Analyst Aish Vivekanandan. “This is because pricing pressures, along with limited return on investment and competition from substitute products, pose a challenge to the use of human albumin in replacement therapy.” 

On the other hand, global increase in the fractionation of blood and rise in demand for human albumin in Asia-Pacific countries, especially India and China, will sustain production rates. In India, regulatory pressures and pricing control of albumin are being eased to meet the therapeutic needs of the population. With shortages in albumin products in the country, global manufacturers are likely to foray into the market, while China’s albumin market grows steadily. 

The evolving need of albumin use as an excipient will also widen existing market opportunities for blood plasma product manufacturers. Going forward, a large number of biotech and biopharmaceutical firms are expected to develop recombinant versions of albumin to explore its potential in extending the half-life and stability to biologics and bio-similars. There are at least 15 products under clinical trial that involve the use of human albumin as an excipient (stabiliser, drug formulation). 

“Some of the key products in which albumin is being used as a drug formulation agent, stabiliser or fusion protein for half-life extension are ABI-009 and rIX-FP,” noted Vivekanandan. “rIX-FP and Albutein for Alzheimer’s disease are expected to be launched in late 2015 and 2020, respectively.” 

Developed by CSL Behring, rIX-FP is a recombinant fusion protein linking coagulation factor IX with albumin. It is indicated for the treatment of hemophilia B, with dosing intervals of up to 14 days. ABI-009 is a nanoparticle albumin-bound version of the mTOR inhibitor sirolimus or rapamycin developed by Celgene, which licensed it out to AADi LLC, a clinical stage biopharmaceutical company. 

Analysis of the Global Human Albumin Market and Product Pipeline is part of the Life Sciences Growth Partnership Service program. Frost & Sullivan’s related studies include: United States and European Diabetes Diagnostics Market, Global Diabetes Drug Delivery Market, Global Clinical Trial and Research Outsourcing Market, and Global Infectious Disease Diagnostics Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. 


more about frost & sullivan


 



 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd

 


Promotions

 

Media Partners